Standout Papers

Atezolizumab Plus Chemotherapy for First-Line Treatment of N... 2016 2026 2019 2022 647
  1. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial (2020)
    Makoto Nishio, Fabrice Barlési et al. Journal of Thoracic Oncology
  2. Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer (2016)
    Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology
  3. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study (2016)
    Scott Antonia, Sarah B. Goldberg et al. The Lancet Oncology

Immediate Impact

4 by Nobel laureates 20 from Science/Nature 61 standout
Sub-graph 1 of 21

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
Natural killer cell therapies
2024 StandoutNature
3 intermediate papers

Works of Rachel E. Sanborn being referenced

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
2017
A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.
2014
and 1 more

Author Peers

Author Last Decade Papers Cites
Rachel E. Sanborn 2715 1255 1083 149 3.6k
Mitsuhiro Takenoyama 2147 1843 1064 222 3.9k
Takeshi Hanagiri 1770 1817 1004 209 3.8k
Leonard J. Appleman 1481 1157 747 176 3.3k
Alexander N. Shoushtari 3235 809 1530 162 4.6k
Dirk Jaeger 3031 1113 1145 87 4.1k
Erminia Massarelli 3100 2060 710 139 4.5k
Jens Atzpodien 2178 1342 1203 140 3.9k
Salvador Martín‐Algarra 2212 906 1110 141 3.8k
Carlos Gomez‐Roca 2329 799 768 147 3.9k
Carl Plager 2367 1211 848 71 3.8k

All Works

Loading papers...

Rankless by CCL
2026